Table 3.

Risk factors for ECEs

MVARisk for ECEs, HR (95% CI)P value
Age, y   
> 60 (vs younger) 1.36 (0.74-2.50) .315 
HTN   
Yes (vs no) 2.01 (1.06-3.80) .030 
DLP   
Yes (vs no) 2.42 (1.20-4.86) .012 
Diabetes mellitus   
Yes (vs no) 0.49 (0.16-1.44) .197 
Previous cardiac pathology   
Yes (vs no) 1.39 (0.68-2.85) .355 
Disease status before allo-HCT   
Active disease (vs complete remission) 1.70 (0.77-3.75) .182 
Conditioning regimen   
MAC regimen containing CY (vs others) 0.85 (0.30-2.42) .773 
GVHD prophylaxis   
PTCY-based prophylaxis (vs other) 2.86 (1.32-6.21) .007 
Donor type   
Haploidentical donors (vs HLA-matched and MMUD) 1.16 (0.57-2.39) .674 
Grade 3-4 aGVHD   
Time-dependent variable 2.19 (0.88-5.43) .088 
MVARisk for ECEs, HR (95% CI)P value
Age, y   
> 60 (vs younger) 1.36 (0.74-2.50) .315 
HTN   
Yes (vs no) 2.01 (1.06-3.80) .030 
DLP   
Yes (vs no) 2.42 (1.20-4.86) .012 
Diabetes mellitus   
Yes (vs no) 0.49 (0.16-1.44) .197 
Previous cardiac pathology   
Yes (vs no) 1.39 (0.68-2.85) .355 
Disease status before allo-HCT   
Active disease (vs complete remission) 1.70 (0.77-3.75) .182 
Conditioning regimen   
MAC regimen containing CY (vs others) 0.85 (0.30-2.42) .773 
GVHD prophylaxis   
PTCY-based prophylaxis (vs other) 2.86 (1.32-6.21) .007 
Donor type   
Haploidentical donors (vs HLA-matched and MMUD) 1.16 (0.57-2.39) .674 
Grade 3-4 aGVHD   
Time-dependent variable 2.19 (0.88-5.43) .088 

Variables included in the multivariate model were selected based on results reported in supplemental Table 1 (univariate regression analysis) and if considered clinically relevant for cardiac toxicity according to previous related publications. Posttransplant follow-up has been censored at 100 days. No event diagnosed after day +100 has been accounted for this analysis.

MMUD, mismatched unrelated donor.

Close Modal

or Create an Account

Close Modal
Close Modal